echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Top10, world's best-selling drug 2025: BMS takes three seats Humira falls to 6th

    Top10, world's best-selling drug 2025: BMS takes three seats Humira falls to 6th

    • Last Update: 2020-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, global Data, the world's leading market research organization, released the "2025 world's best-selling drug TOP10" list, it is predicted that the Mercadon immuno-oncology drugKeytrudawill become the best-selling drugs in 2023, sales in 2025 will reach $22.2 billionKeytruda has been the most important product in Mercado since it was approved by the FDA in 2015To date, Keytruda has received approval for more than 20 oncology indications in the United StatesWith the industry's largest immuno-oncology program, Mercado is continuing to expand new indications and markets around the worldKeytruda's sales in the first nine months of the year reached $7.973 billion, up 58.8 percent from a year earlierranked 2ndis the BMS/Pfizer's oral anticoagulantEliquis, which will continue its strong growth momentum, with sales expected to reach $18.7 billion in 2025thirdis the new base's heavy immunomodulator
    Revlimid, which is expected to generate $12.4 billion in sales in 2025, although the drug will also be affected by genericsIn the U.S., Revlimid generics is expected to hit the market in 2022The fourth on the list is the Opdivo of BMS, which is expected to generate $12 billion in sales in 2025 and is Keytruda's leading competitor in immuno-oncology Opdivo's sales in the first nine months of the year were $5.441 billion, up 10 percent from the same period last year The BMS-New Base merger is currently in progress and Revlimid will be owned by BMS upon completion of the acquisition It also means that BMS will have three products in its hands on the 2025 top10 list of the world's best-selling drugs - Eliquis, Revlimid and Opdivo - with combined sales of $43.1 billion in 2025 ranked 5th in the is the Imbruvica of the BTK inhibitor of The Company, which is expected to generate sales of $11.9 billion in 2025 Since its launch in November 2013, the drug has approved up to 10 therapeutic indications in a total of six disease areas, including five B-cell blood cancers and chronic transplant anti-host disease Both sides are currently advancing Imbruvica's massive clinical development project the 6th is AbbVie's flagship Humira , the world's best-selling drug In Europe, Humira sales fell sharply due to competition from biosimilars Humira is set to give way as the U.S market competes for biosimilars in 2023, with sales expected to fall to $10.3 billion by 2025 The 7th is gilead Science's , a new three-in-one HIV drug , with sales expected to reach $10 billion by 2025 The drug was approved by the FDA in February 2018 and is currently available as a complete treatment for first- and second-line treatments for people infected with HIV-1 adults and children (weighing 25 kg) Since its launch, Biktarvy's sales have risen sharply, to more than $1 billion in its first year The drug reported sales of $3.168 billion in the first nine months of the year, up 423 percent from $606 million a year earlier ranked 8-10 are Pfizer's breast cancer drug Ibrance , Johnson and Johnson's immune student products Stelara , Lilly's sugar-lowering drug Trulicity , with sales expected to be $9,75 billion and $7.2 billion in 2025 Ibrance is the world's first and best-selling CDK4/6 inhibitor, with sales of $4.118 billion in 2018 Stelara is a core product of Johnson and Johnson's autoimmune diseases, which was first launched in Canada in December 2008 and generated $5.3 billion in sales in 2018, although its patent protection sit in the United States and the European Union in September 2023 and July 2024, respectively Trulicity, a weekly injection of glucagon-like peptide-1 receptor agonists, was approved for sale in September 2014 and generated $3.2 billion in sales in 2018. 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.